Gilead Sciences
$149.05Change from previous close: −1.47%Absolute change: −$2.23
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $184.82B
- Enterprise value
- $206.1B
- P/E (trailing 12 months)
- -56.5
- Forward P/E
- 15.1
- PEG
- 2.22
- Price/book
- 15.6
- Price/sales
- 6.07
- EV/EBITDA
- 14.1
- EV/revenue
- 6.77
Profitability and growth
- Gross margin
- 79.6%
- Operating margin
- 33.7%
- Net margin
- -10.6%
- ROE
- -20.7%
- ROA
- 14.1%
- Revenue growth (year over year)
- 10.2%
Financial health
- Total cash
- $4.88B
- Total debt
- $26.25B
- Debt/equity
- 2.23
- Current ratio
- 1.27
- Quick ratio
- 0.90
Dividends
- Annual dividend per share
- $3.28
- Dividend yield
- 2.2%
- Payout ratio
- 43.4%
- Ex-dividend date
- September 15, 2026
Analysts and estimates
- Average price target
- $158.65
- Median price target
- $163.50
- High price target
- $180.00
- Low price target
- $123.00
- Number of analysts
- 26
- Consensus
- Buy
- Forward EPS
- $9.89
- EPS estimate, current year
- -$0.43
Shares and trading
- Beta
- 0.35
- Average volume
- 6.31M
- Shares outstanding
- 1.24B
- Float
- 1.24B
- Institutional ownership
- 92.2%
- Insider ownership
- 0.1%
- Short interest (% of float)
- 1.5%
- Short ratio (days)
- 3.45